PerpEquities

Equity · Healthcare

Amgen Inc. (AMGN) perpetual futures

AMGN perpetual futures on 7 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade AMGNUSDT.

Amgen Inc. is a global biotechnology company that develops and sells medicines for inflammatory, oncological, bone, cardiovascular, and other diseases.

$382.61+1.1%NASDAQ closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

Collecting venue price data...
venue perp mark · BingX (AMGN-USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

7/7 live markets
Venues
7
Live markets
7/7
24h volume
$443.7KCoverage: 6/7 marketsExchange-reported volume: $1.7M
Open interest
$252.5KCoverage: 6/7 markets
Best liquidity
$452.1K
Bitget
Tightest spread
+11.8 bps
Bitget
Highest volume
$312.7K
HTX
Settlement mix
USDT · 5/7
Perp/spot vol.
0.00x
Spot volume $145.9M
OI / float
0.00%
Float $205.9B
Spot performance
1D+0.20%
5D-3.81%
1M-8.94%
6M+3.25%
YTD+15.52%
1Y+37.79%

Venue matrix

7 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
BingXTradeAMGN-USDTTrading$383.05+5.5% APR
+0.00500% every 8h
+23.2 bps$14.6K$1.2M$3.7KUSDT-
HTXTradeAMGN/USDTTrading$385.100.0% APR
0.000% every 8h
+122.3 bps$30.3K$312.7K$5.7KUSDT-
BitgetTradeAMGN/USDTTrading$382.610.0% APR
0.000% every 8h
+11.8 bps$452.1K$53.1K$66.1KUSDT20x
Helix (Injective)TradeAMGN/USDCTrading$381.98+3.6% APR
+0.00042% every 1h
--$49.9K-USDC12x
BybitTradeAMGN/USDTTrading$382.840.0% APR
0.000% every 8h
+23.0 bps$12.6K$22K$94.2KUSDT25x
Gate.ioTradeAMGN/USDTTrading$383.300.0% APR
0.000% every 8h
+60.0 bps$9.5K$6K$63.3KUSDT20x
ExtendedTradeAMGN/USDTrading$381.73+4.4% APR
+0.00050% every 1h
+61.4 bps$200K$0$19.5KUSD10x

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

Adequate liquidity · 5 of 7 venues absorb $10k · Typical cost: +38.2 bps – +93.6 bps

Cheapest execution: Bitget · +12.8 bps

No fresh book data: HTX, Helix (Injective)

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

AMGN

Tightest spread

AMGN

Highest volume

AMGN

Funding history

Stored venue snapshots by market

Company data

Company fundamentals

Updated 2h ago
Market cap
$204.9B
Updated 2h ago
Revenue
$38.1B
Trailing 12 months
Revenue growth
+6%
Next fiscal year
Profit margin
+22.9%
P/E
23.4
Peer P/E 20.0
Free cash flow
$10.2B
Trailing 12 months
More metrics
Net income
$8.7B
Trailing 12 months
P/S
5.4
Peer P/E
20.0
Similar listed perps
Revenue estimate
$39B
Next fiscal year
Earnings
2026-11-03
Revenue est. $10B · Updated 2h ago
Dividend
$2.52
2026-08-21

Fundamental detail

Annual + quarterly
Latest revenue$36.7B
Net margin+21.0%
Free cash flow$8.1B
Net debt$45.5B
2020$25.4B
2021$26B
2022$26.3B
2023$28.2B
2024$33.4B
2025$36.7B
PeriodRevenueGrowthNet incomeFCF
2020$25.4B+9%$7.3B$9.9B
2021$26B+2%$5.9B$8.4B
2022$26.3B+1%$6.6B$8.8B
2023$28.2B+7%$6.7B$7.4B
2024$33.4B+19%$4.1B$10.4B
2025$36.7B+10%$7.7B$8.1B
PeriodGross marginOperating marginNet marginROEROA
2020+75.8%+35.9%+28.6%+77.2%+11.5%
2021+75.2%+29.4%+22.7%+88.0%+9.6%
2022+75.7%+36.3%+24.9%+179.0%+10.1%
2023+70.1%+28.0%+23.8%+107.8%+6.9%
2024+61.5%+21.7%+12.2%+69.6%+4.5%
2025+70.8%+29.1%+21.0%+89.1%+8.5%
PeriodCashDebtNet debtCurrent ratio
2020$6.3B$33B$26.7B1.81
2021$8B$33.3B$25.3B1.59
2022$7.6B$38.9B$31.3B1.41
2023$10.9B$64.6B$53.7B1.65
2024$12B$60.1B$48.1B1.26
2025$9.1B$54.6B$45.5B1.14
PeriodMarket capEnterprise valueP/SP/E
2020$134.7B$161.5B5.318.5
2021$128.2B$153.6B4.921.8
2022$141.3B$172.6B5.421.6
2023$154.1B$207.8B5.522.9
2024$141B$189.1B4.234.2
2025$176.1B$221.6B4.822.8
Q3 2024$8.5B
Q4 2024$9.1B
Q1 2025$8.1B
Q2 2025$9.2B
Q3 2025$9.6B
Q4 2025$9.9B
Q1 2026$8.6B
Q2 2026$10.1B
PeriodRevenueGrowthNet incomeFCF
Q3 2024$8.5B+23%$2.8B$3.3B
Q4 2024$9.1B+11%$627M$4.4B
Q1 2025$8.1B+9%$1.7B$980M
Q2 2025$9.2B+9%$1.4B$1.9B
Q3 2025$9.6B+12%$3.2B$4.2B
Q4 2025$9.9B+9%$1.3B$961M
Q1 2026$8.6B+6%$1.8B$1.5B
Q2 2026$10.1B+10%$2.4B$3.5B
PeriodGross marginOperating marginNet marginROEROA
Q3 2024+61.1%+24.1%+33.3%+37.6%+3.1%
Q4 2024+65.7%+25.4%+6.9%+10.7%+0.7%
Q1 2025+63.6%+14.5%+21.2%+27.9%+1.9%
Q2 2025+67.2%+28.8%+15.6%+19.3%+1.6%
Q3 2025+67.8%+26.4%+33.7%+33.4%+3.6%
Q4 2025+81.9%+39.8%+13.5%+15.4%+1.5%
Q1 2026+68.2%+30.9%+21.1%+19.8%+2.0%
Q2 2026+72.0%+35.0%+23.6%+20.3%+2.5%
PeriodCashDebtNet debtCurrent ratio
Q3 2024$9B$60.4B$51.4B1.32
Q4 2024$12B$60.1B$48.1B1.26
Q1 2025$8.8B$57.4B$48.6B1.17
Q2 2025$8B$56.2B$48.2B1.31
Q3 2025$9.4B$54.6B$45.1B1.28
Q4 2025$9.1B$54.6B$45.5B1.14
Q1 2026$12B$57.3B$45.3B1.26
Q2 2026$14B$57.3B$43.3B1.37
PeriodMarket capEnterprise valueP/SP/E
Q3 2024$173B$224.4B20.315.3
Q4 2024$140.9B$189B15.555.7
Q1 2025$167.6B$216.2B20.624.2
Q2 2025$150.2B$198.4B16.426.2
Q3 2025$151.8B$197B15.911.8
Q4 2025$176.4B$221.9B17.833.1
Q1 2026$190B$235.3B22.026.1
Q2 2026$195.5B$238.9B19.420.6

Refreshed 2h ago

Charts: revenue, profit, cash flow & valuation
Revenue$10.1BQ2 2026
$2.5B$5B$7.5B$10.1BQ3 2023: $6.9BQ4 2023: $8.2BQ1 2024: $7.4BQ2 2024: $8.4BQ3 2024: $8.5BQ4 2024: $9.1BQ1 2025: $8.1BQ2 2025: $9.2BQ3 2025: $9.6BQ4 2025: $9.9BQ1 2026: $8.6BQ2 2026: $10.1BQ3 2023Q2 2026
Net income$2.4BQ2 2026
$719.3M$1.6B$2.4B$3.2BQ3 2023: $1.7BQ4 2023: $767MQ1 2024: -$113MQ2 2024: $746MQ3 2024: $2.8BQ4 2024: $627MQ1 2025: $1.7BQ2 2025: $1.4BQ3 2025: $3.2BQ4 2025: $1.3BQ1 2026: $1.8BQ2 2026: $2.4BQ3 2023Q2 2026
EBITDA$3.4BQ2 2026
$1.5B$3B$4.4B$5.9BQ3 2023: $3.6BQ4 2023: $3.1BQ1 2024: $2.2BQ2 2024: $3BQ3 2024: $5.3BQ4 2024: $2.9BQ1 2025: $4.1BQ2 2025: $3.6BQ3 2025: $5.9BQ4 2025: $3.3BQ1 2026: $3.9BQ2 2026: $3.4BQ3 2023Q2 2026
Free cash flow$3.5BQ2 2026
$1.1B$2.2B$3.3B$4.4BQ3 2023: $2.5BQ4 2023: $289MQ1 2024: $459MQ2 2024: $2.2BQ3 2024: $3.3BQ4 2024: $4.4BQ1 2025: $980MQ2 2025: $1.9BQ3 2025: $4.2BQ4 2025: $961MQ1 2026: $1.5BQ2 2026: $3.5BQ3 2023Q2 2026
EPS$4.37Q2 2026
$1.33$2.86$4.4$5.93Q3 2023: $3.22Q4 2023: $1.42Q1 2024: -$0.21Q2 2024: $1.38Q3 2024: $5.22Q4 2024: $1.16Q1 2025: $3.2Q2 2025: $2.65Q3 2025: $5.93Q4 2025: $2.45Q1 2026: $3.34Q2 2026: $4.37Q3 2023Q2 2026
Cash / Debt$14BQ2 2026
$16.2B$32.3B$48.5B$64.6BQ3 2023 · Cash: $34.7BQ3 2023 · Debt: $60.5BQ4 2023 · Cash: $10.9BQ4 2023 · Debt: $64.6BQ1 2024 · Cash: $9.7BQ1 2024 · Debt: $64BQ2 2024 · Cash: $9.3BQ2 2024 · Debt: $62.6BQ3 2024 · Cash: $9BQ3 2024 · Debt: $60.4BQ4 2024 · Cash: $12BQ4 2024 · Debt: $60.1BQ1 2025 · Cash: $8.8BQ1 2025 · Debt: $57.4BQ2 2025 · Cash: $8BQ2 2025 · Debt: $56.2BQ3 2025 · Cash: $9.4BQ3 2025 · Debt: $54.6BQ4 2025 · Cash: $9.1BQ4 2025 · Debt: $54.6BQ1 2026 · Cash: $12BQ1 2026 · Debt: $57.3BQ2 2026 · Cash: $14BQ2 2026 · Debt: $57.3BQ3 2023Q2 2026
CashDebt
Profitability+72.0%Q2 2026
+19.3%+40.2%+61.1%+81.9%Q3 2023 · Gross margin: +73.8%Q4 2023 · Gross margin: +62.0%Q1 2024 · Gross margin: +57.0%Q2 2024 · Gross margin: +61.4%Q3 2024 · Gross margin: +61.1%Q4 2024 · Gross margin: +65.7%Q1 2025 · Gross margin: +63.6%Q2 2025 · Gross margin: +67.2%Q3 2025 · Gross margin: +67.8%Q4 2025 · Gross margin: +81.9%Q1 2026 · Gross margin: +68.2%Q2 2026 · Gross margin: +72.0%Q3 2023 · Operating margin: +29.3%Q4 2023 · Operating margin: +15.5%Q1 2024 · Operating margin: +13.3%Q2 2024 · Operating margin: +22.8%Q3 2024 · Operating margin: +24.1%Q4 2024 · Operating margin: +25.4%Q1 2025 · Operating margin: +14.5%Q2 2025 · Operating margin: +28.8%Q3 2025 · Operating margin: +26.4%Q4 2025 · Operating margin: +39.8%Q1 2026 · Operating margin: +30.9%Q2 2026 · Operating margin: +35.0%Q3 2023 · Net margin: +25.1%Q4 2023 · Net margin: +9.4%Q1 2024 · Net margin: -1.5%Q2 2024 · Net margin: +8.9%Q3 2024 · Net margin: +33.3%Q4 2024 · Net margin: +6.9%Q1 2025 · Net margin: +21.2%Q2 2025 · Net margin: +15.6%Q3 2025 · Net margin: +33.7%Q4 2025 · Net margin: +13.5%Q1 2026 · Net margin: +21.1%Q2 2026 · Net margin: +23.6%Q3 2023Q2 2026
Gross marginOperating marginNet margin
Revenue growth+9.7%Q2 2026
+5.8%+11.6%+17.4%+23.2%Q2 2024: +20.1%Q3 2024: +23.2%Q4 2024: +10.9%Q1 2025: +9.4%Q2 2025: +9.3%Q3 2025: +12.4%Q4 2025: +8.9%Q1 2026: +5.8%Q2 2026: +9.7%Q3 2023Q2 2026
Shares outstanding544MQ2 2026
136M272M408M544MQ3 2023: 538MQ4 2023: 540MQ1 2024: 536MQ2 2024: 541MQ3 2024: 542MQ4 2024: 542MQ1 2025: 541MQ2 2025: 541MQ3 2025: 542MQ4 2025: 543MQ1 2026: 544MQ2 2026: 544MQ3 2023Q2 2026
Valuation20.6Q2 2026
-238.7-140.5-42.355.9Q3 2023 · P/E: 20.8Q4 2023 · P/E: 50.4Q1 2024 · P/E: -337.0Q2 2024 · P/E: 55.9Q3 2024 · P/E: 15.3Q4 2024 · P/E: 55.7Q1 2025 · P/E: 24.2Q2 2025 · P/E: 26.2Q3 2025 · P/E: 11.8Q4 2025 · P/E: 33.1Q1 2026 · P/E: 26.1Q2 2026 · P/E: 20.6Q3 2023 · P/S: 20.8Q4 2023 · P/S: 18.8Q1 2024 · P/S: 20.4Q2 2024 · P/S: 19.9Q3 2024 · P/S: 20.3Q4 2024 · P/S: 15.5Q1 2025 · P/S: 20.6Q2 2025 · P/S: 16.4Q3 2025 · P/S: 15.9Q4 2025 · P/S: 17.8Q1 2026 · P/S: 22.0Q2 2026 · P/S: 19.4Q3 2023Q2 2026
P/EP/S
Revenue$36.7B2025
$9.2B$18.4B$27.6B$36.7B2018: $23.7B2019: $23.4B2020: $25.4B2021: $26B2022: $26.3B2023: $28.2B2024: $33.4B2025: $36.7B20182025
Net income$7.7B2025
$2.1B$4.2B$6.3B$8.4B2018: $8.4B2019: $7.8B2020: $7.3B2021: $5.9B2022: $6.6B2023: $6.7B2024: $4.1B2025: $7.7B20182025
EBITDA$16.9B2025
$4.2B$8.4B$12.7B$16.9B2018: $12.9B2019: $12.6B2020: $13B2021: $11.3B2022: $12.2B2023: $14.8B2024: $13.4B2025: $16.9B20182025
Free cash flow$8.1B2025
$2.6B$5.3B$7.9B$10.6B2018: $10.6B2019: $8.5B2020: $9.9B2021: $8.4B2022: $8.8B2023: $7.4B2024: $10.4B2025: $8.1B20182025
EPS$14.22025
$3.56$7.12$10.7$14.22018: $12.62019: $12.92020: $12.32021: $10.32022: $12.12023: $12.52024: $7.562025: $14.220182025
Cash / Debt$9.1B2025
$16.2B$32.3B$48.5B$64.6B2018 · Cash: $6.9B2018 · Debt: $33.9B2019 · Cash: $6B2019 · Debt: $29.9B2020 · Cash: $6.3B2020 · Debt: $33B2021 · Cash: $8B2021 · Debt: $33.3B2022 · Cash: $7.6B2022 · Debt: $38.9B2023 · Cash: $10.9B2023 · Debt: $64.6B2024 · Cash: $12B2024 · Debt: $60.1B2025 · Cash: $9.1B2025 · Debt: $54.6B20182025
CashDebt
Profitability+70.8%2025
+20.7%+41.4%+62.0%+82.7%2018 · Gross margin: +82.7%2019 · Gross margin: +81.4%2020 · Gross margin: +75.8%2021 · Gross margin: +75.2%2022 · Gross margin: +75.7%2023 · Gross margin: +70.1%2024 · Gross margin: +61.5%2025 · Gross margin: +70.8%2018 · Operating margin: +43.2%2019 · Operating margin: +41.4%2020 · Operating margin: +35.9%2021 · Operating margin: +29.4%2022 · Operating margin: +36.3%2023 · Operating margin: +28.0%2024 · Operating margin: +21.7%2025 · Operating margin: +29.1%2018 · Net margin: +35.3%2019 · Net margin: +33.6%2020 · Net margin: +28.6%2021 · Net margin: +22.7%2022 · Net margin: +24.9%2023 · Net margin: +23.8%2024 · Net margin: +12.2%2025 · Net margin: +21.0%20182025
Gross marginOperating marginNet margin
Revenue growth+9.9%2025
+3.4%+8.5%+13.5%+18.6%2019: -1.6%2020: +8.8%2021: +2.2%2022: +1.3%2023: +7.1%2024: +18.6%2025: +9.9%20182025
Shares outstanding542M2025
166.3M332.5M498.8M665M2018: 665M2019: 609M2020: 590M2021: 573M2022: 541M2023: 538M2024: 541M2025: 542M20182025
Valuation22.82025
8.617.125.734.22018 · P/E: 15.32019 · P/E: 18.62020 · P/E: 18.52021 · P/E: 21.82022 · P/E: 21.62023 · P/E: 22.92024 · P/E: 34.22025 · P/E: 22.82018 · P/S: 5.42019 · P/S: 6.22020 · P/S: 5.32021 · P/S: 4.92022 · P/S: 5.42023 · P/S: 5.52024 · P/S: 4.22025 · P/S: 4.820182025
P/EP/S

Next catalyst

Catalysts

Earnings
2026-11-03
Revenue est. $10B · Updated 2h ago
Dividend
$2.52
2026-08-21

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 202623.08$39B+6%20
FY 202724.42$40.3B+10%20
FY 202825.74$41.6B+13%11
FY 202927.37$43.1B+17%4
FY 203029.14$44.8B+22%4
Q1 20275.60$9.4B+9%7

Company events

6
2026-11-03EarningsActual - / Estimate 5.79-
2026-08-21Dividend$2.52-
2026-08-04EarningsActual 6.29 / Estimate 5.62Beat
2026-05-15Dividend$2.52-
2026-04-30EarningsActual 5.15 / Estimate 4.77Beat
2026-02-13Dividend$2.52-

Peer comparison

Similar listed perps

FMP company data

Company intelligence

Updated: Sep 14, 2026, 08:27 PM UTC

Company profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Chief executive
Robert A. Bradway
Employees
31,500
IPO date
Jun 17, 1983
Country
US
Exchange
NASDAQ Global Select
Website
Altman Z-scorei2.1
Piotroski scorei8/9
FMP ratingiB+
Owner earningsi$3.67B$6.75 per share
ESG risk ratingiBIndustry rank: 18 out of 27

Rating factors

Return on equityi
5
Return on assetsi
5
Debt to equityi
1
Price to earningsi
2
Price to booki
1
Market cap history
$203.77B+7.7%Jun 26Sep 26
$186.15B$212.91B$239.67BHigh: $239.67B · 2026-08-24Low: $186.15B · 2026-06-22Latest: $203.77B · 2026-09-11Jun 26Jul 26Aug 26Sep 26
Latest: $203.77B · 2026-09-11High: $239.67B · 2026-08-24Low: $186.15B · 2026-06-22
Largest fund holders
FundWeightShares held
VCPA.S0.53%25.1M
VTI0.29%17.2M
VOO0.32%14.2M
SCHD4.31%12.4M
VSCA.S0.38%11.5M
QQQ0.92%11.5M
FXAIX0.32%7M
IVV0.32%6.9M
1657.T0.24%6.9M
SPY0.32%6.6M
VTV0.77%5.1M
DIA4.36%5.1M

Analyst track record

How the analysts covering AMGN have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings207621
Analysts3646
Buy / hold / sell108 / 89 / 10347 / 237 / 37
Upgrades / downgrades / initiations3 / 4 / 510 / 9 / 15
Price targets hit / missed112 / 68 (62%)451 / 87 (84%)
Avg. return after a rating (TipRanks)+5.6%+15.4%
Best / worst call+66.3% / -16.9%+106.7% / -16.9%

After buy calls on this stock: median 21-day move +0.1% vs S&P 500 -2.2% (n = 339)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. David AmsellemPiper Sandler100% hit rate on this stock · 26 targets measuredBuytarget $457Sep 8, 2026
  2. Mohit BansalWells Fargo100% hit rate on this stock · 14 targets measuredHoldtarget $435Sep 4, 2026
  3. Gregory RenzaTruist Financial75% hit rate on this stock · 16 targets measuredHoldno targetSep 8, 2026

Latest ratings

DateAnalystCallTarget
Sep 9, 2026Morten HerholdtHSBCHoldDowngraded$425
Sep 9, 2026Louise ChenScotiabankBuyMaintained$450
Sep 9, 2026Geoff MeachamCitiHoldMaintained$405
Sep 8, 2026Tazeen AhmadBank of America SecuritiesSellMaintained$317
Sep 8, 2026Yaron WerberTD CowenBuyReiterated$452
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$300$320$340$360$380$400$420$440Oct 25 · Buy 11 · Hold 12 · Sell 1Oct 25Nov 25 · Buy 11 · Hold 12 · Sell 1Dec 25 · Buy 11 · Hold 12 · Sell 1Dec 25Jan 26 · Buy 12 · Hold 13 · Sell 2Feb 26 · Buy 14 · Hold 13 · Sell 2Feb 26Mar 26 · Buy 14 · Hold 13 · Sell 2Apr 26 · Buy 14 · Hold 13 · Sell 2Apr 26May 26 · Buy 14 · Hold 15 · Sell 1Jun 26 · Buy 13 · Hold 15 · Sell 1Jun 26Jul 26 · Buy 11 · Hold 14 · Sell 1Aug 26 · Buy 12 · Hold 15 · Sell 2Aug 26Sep 26 · Buy 11 · Hold 16 · Sell 2Oct 25 · avg. target $327Nov 25 · avg. target $333Dec 25 · avg. target $340Jan 26 · avg. target $345Feb 26 · avg. target $361Mar 26 · avg. target $365Apr 26 · avg. target $367May 26 · avg. target $365Jun 26 · avg. target $363Jul 26 · avg. target $360Aug 26 · avg. target $389Sep 26 · avg. target $394Oct 25 · month-end close $298Nov 25 · month-end close $345Dec 25 · month-end close $327Jan 26 · month-end close $342Feb 26 · month-end close $388Mar 26 · month-end close $352Apr 26 · month-end close $346May 26 · month-end close $337Jun 26 · month-end close $362Jul 26 · month-end close $385Aug 26 · month-end close $430Sep 26 · month-end close $382

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data via FMP · computed Sep 11, 2026 · 207 ratings

Frequently asked questions

Where can I trade AMGN perpetual futures?

Amgen Inc. (AMGN) perpetual futures trade on 7 crypto venues, including BingX, HTX, Bitget. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade AMGN around the clock?

Yes. Unlike the underlying stock, AMGN perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on AMGN perpetuals?

Right now the AMGN perp funding rate is 0.0% annualized (venue median), ranging from 0.0% to +5.5% across 7 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the AMGN perp price compare to the Amgen Inc. stock?

The venue-median AMGN perp mark is $382.8 versus a reference stock price of $382.6, a basis of +0.1%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a AMGN perpetual future?

A AMGN perpetual is a derivative that tracks the price of Amgen Inc. with no expiry date. It lets you take long or short exposure to Amgen Inc. on crypto venues, around the clock.

What is AMGNUSDT perpetual?

AMGNUSDT is the symbol most crypto exchanges use for the Amgen Inc. perpetual settled in USDT (Tether). It tracks the AMGN share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

AMGN perpetuals · perpequities.comAMGN perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/amgn-perp"><img src="https://perpequities.com/badge/amgn-perp.svg" width="240" height="64" alt="AMGN perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of AMGN perps

Weekly digest by email

The listings, funding and moves that matter for AMGN — one email every Sunday.

Watchlist and alerts

Price and funding alerts for AMGN, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X